Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giovanni Martinelli

Showing results (41-50 of 657) with videos related to

Pageof 66
Sort By:
The Lancet. Infectious Diseases|March 31, 2004
Babesia infection in ItalyPier Paolo Piccaluga, Giovanni Poletti, Giovanni Martinelli, et al.
Journal of Hematology & Oncology|November 28, 2019
The balance between mitotic death and mitotic slippage in acute leukemia: a new therapeutic window?Andrea Ghelli Luserna di Rorà, Giovanni Martinelli, Giorgia Simonetti
British Journal of Haematology|March 8, 2016
Present and future of molecular monitoring in chronic myeloid leukaemiaSimona Soverini, Caterina De Benedittis, Manuela Mancini, et al.
Blood Cancer Discovery|October 18, 2021
Hedgehog Pathway Inhibitors: A New Therapeutic Class for the Treatment of Acute Myeloid LeukemiaCatriona Jamieson, Giovanni Martinelli, Cristina Papayannidis, et al.
Frontiers in Genetics|December 1, 2022
From phenotypical investigation to RNA-sequencing for gene expression analysis: A workflow for single and pooled rare cellsTania Rossi, Davide Angeli, Giovanni Martinelli, et al.
Panminerva Medica|September 21, 2020
Allogenic stem cell transplantation in multiple myeloma: dead or alive and kicking?Massimo Martino, Annalisa Paviglianiti, Massimo Gentile, et al.
Hematology Reports|August 22, 2023
How I Manage Chronic Lymphocytic LeukemiaPatrice Nasnas, Claudio Cerchione, Gerardo Musuraca, et al.
Frontiers in Oncology|December 2, 2020
Multiple Myeloma Outpatient Transplant Program in the Era of Novel Agents: State-of-the-ArtMassimo Martino, Annalisa Paviglianiti, Mara Memoli, et al.
The Oncologist|June 3, 2011
Choosing the best second-line tyrosine kinase inhibitor in imatinib-resistant chronic myeloid leukemia patients harboring Bcr-Abl kinase domain mutations: how reliable is the IC₅₀?Simona Soverini, Gianantonio Rosti, Ilaria Iacobucci, et al.
International Journal of Cancer|July 8, 2018
Aneuploidy: Cancer strength or vulnerability?Giorgia Simonetti, Samantha Bruno, Antonella Padella, et al.
Pageof 66

Showing results (41-50 of 657) with videos related to

Sort By:
Pageof 66
The Lancet. Infectious Diseases|March 31, 2004
Babesia infection in ItalyPier Paolo Piccaluga, Giovanni Poletti, Giovanni Martinelli, et al.
Journal of Hematology & Oncology|November 28, 2019
The balance between mitotic death and mitotic slippage in acute leukemia: a new therapeutic window?Andrea Ghelli Luserna di Rorà, Giovanni Martinelli, Giorgia Simonetti
British Journal of Haematology|March 8, 2016
Present and future of molecular monitoring in chronic myeloid leukaemiaSimona Soverini, Caterina De Benedittis, Manuela Mancini, et al.
Blood Cancer Discovery|October 18, 2021
Hedgehog Pathway Inhibitors: A New Therapeutic Class for the Treatment of Acute Myeloid LeukemiaCatriona Jamieson, Giovanni Martinelli, Cristina Papayannidis, et al.
Frontiers in Genetics|December 1, 2022
From phenotypical investigation to RNA-sequencing for gene expression analysis: A workflow for single and pooled rare cellsTania Rossi, Davide Angeli, Giovanni Martinelli, et al.
Panminerva Medica|September 21, 2020
Allogenic stem cell transplantation in multiple myeloma: dead or alive and kicking?Massimo Martino, Annalisa Paviglianiti, Massimo Gentile, et al.
Hematology Reports|August 22, 2023
How I Manage Chronic Lymphocytic LeukemiaPatrice Nasnas, Claudio Cerchione, Gerardo Musuraca, et al.
Frontiers in Oncology|December 2, 2020
Multiple Myeloma Outpatient Transplant Program in the Era of Novel Agents: State-of-the-ArtMassimo Martino, Annalisa Paviglianiti, Mara Memoli, et al.
The Oncologist|June 3, 2011
Choosing the best second-line tyrosine kinase inhibitor in imatinib-resistant chronic myeloid leukemia patients harboring Bcr-Abl kinase domain mutations: how reliable is the IC₅₀?Simona Soverini, Gianantonio Rosti, Ilaria Iacobucci, et al.
International Journal of Cancer|July 8, 2018
Aneuploidy: Cancer strength or vulnerability?Giorgia Simonetti, Samantha Bruno, Antonella Padella, et al.
Pageof 66